Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Solid Biosciences
Thumbnail
February 24, 2022

Amicus exits gene therapy

Spac backtrack confirms that the gene therapy bubble has burst

Thumbnail
January 11, 2022

JP Morgan 2022 – Sarepta gets another bite at the gene therapy cherry

But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.

Article image
Vantage logo
September 29, 2021

Pfizer adds to gene therapy woes

But another safety scare for the big pharma’s Duchenne muscular dystrophy project could be good news for Sarepta.

Article image
Vantage logo
September 01, 2021

Astellas’s gene therapy aspirations crumble

AT132 has prompted more safety concerns, this time at a lower dose than before.

Article image
Vantage logo
March 29, 2021

Uniqure tries to restore gene therapy calm

Article image
Vantage logo
March 16, 2021

Gene therapy data shake Solid

Better-looking safety might not be enough to get Solid back in the Duchenne muscular dystrophy game.

Article image
Vantage logo
January 08, 2021

Gene therapy trial fails to rectify Sarepta’s sorry record

Sarepta’s first ever controlled study, of a Duchenne muscular dystrophy gene therapy, brings the markets down to earth.

Article image
Vantage logo
December 23, 2020

Voyager hold adds to gene therapy woes

Article image
Vantage logo
May 18, 2020

Sarepta gains on Pfizer's setback

Article image
Vantage logo
January 07, 2020

A handful of huge gains stand out among mid and small-cap biotechs

Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.

Article image
Vantage logo
December 19, 2019

Gene therapy clinical holds take centre stage

An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.